Central Venous Access Device-related *Bacillus Cereus* Endocarditis: A Case Report and Review of the Literature

William F. Wright, DO, MPH, FCAP

**Corresponding Author:**
William F. Wright, DO, MPH, FCAP
Infectious Diseases, Department of Medicine
Memorial Medical Center
1600 Sixth Avenue, Suite 114
York, Pennsylvania 17403-2643
Tel: (717) 755-1244
Fax: (717) 757-7644
Email: william.wright.f@gmail.com

Received: December 1, 2015
1st Revision: January 26, 2016
2nd Revision: February 14, 2016
Accepted: February 19, 2016
doi:10.3121/cmr.2016.1312

*Bacillus cereus* endocarditis
Abstract

*Bacillus cereus* typically presents as a gastrointestinal infection, but rarely manifests as systemic disease. This report describes a case of *Bacillus cereus* related endocarditis that presented as a sickle cell crisis and bacteremia. Initial clinical suspicion was for laboratory contamination of blood cultures. The case herein described is intended to demonstrate an uncommon presentation of *Bacillus cereus* infection and highlights the value of an aggressive need to further investigate and interpret unexpected blood culture findings in clinical practice, early adequate antimicrobial therapy, prompt diagnosis, and consideration to urgent surgical interventions in such cases.

**Keywords:** *Bacillus cereus; Bacillus* species; Bacteremia; Central venous catheter infection; Infective endocarditis
Introduction

_Bacillus cereus_ is a rapidly growing gram-positive, aerobic-to facultative, spore forming rod that exists ubiquitously in the environment, for example in soil, dust, and plants (1, 2, 3). The bacterium is also frequently present in food production processes resulting in ingestion of small numbers to participate as part of the transitory human intestinal flora (1). Among _Bacillus_ species, _Bacillus cereus_ is the most common in association with gastrointestinal infections as a result of food poisoning (2, 3). In addition, this species can occasionally cause severe local and systemic infections such as bacteremia, bacterial pneumonia, meningitis, brain abscess, endophthalmitis, ocular keratitis, necrotizing skin and soft-tissue infections, osteomyelitis, pyelonephritis, and endocarditis (1, 2, 3). Organisms are no longer commonly considered "laboratory contaminants" and an association between _Bacillus_ species and deep-seated infections has been established, especially among immunocompromised patients, those with central venous catheters, and history of intravenous drug use (1, 2, 3). Endocarditis related _Bacillus cereus_ infection is a rare clinical presentation, and little is known about its clinical characteristics, treatment, and prognosis. Here the first case, to this author’s knowledge, of _Bacillus cereus_ endocarditis related to a tunneled central venous access device without a history of intravenous drug use is reported followed by a review of the published literature.

Case Presentation

A 27-year-old male was admitted to our hospital experiencing generalized joint pains and fevers for approximately 2-weeks. He had no history of orthopedic surgery, joint trauma, or intraarticular injections. He has a history of sickle cell disease (SCD) classified as sickle cell
*anemia* (homozygous mutation; HbSS) complicated by autosplenectomy and left middle cerebral artery territory ischemic stroke at age 8-years with residual right upper extremity hemiplegia. The patient has been maintained on disease-modifying therapy with hydroxyurea and folic acid for 19 years. Three years prior to his present admission, he experienced a crisis episode that required exchange transfusion and subsequent placement of a right internal jugular vein tunneled central venous access device (PORT-A-CATH®) through the anterior chest wall. On physical examination, he was afebrile (99.1°C; 37.3°C), and all other vital signs within normal limits except tachycardia (pulse 110 beats per minute). Precordium examination revealed normal first and second heart sounds with a soft, grade 1/6 systolic murmur heard best along the left sternal border and louder with inspiration. Cardiovascular examination did not demonstrate a palpable thrill or elevated jugular venous pressure. His musculoskeletal examination demonstrated no effusions or abnormalities with normal range of motion except flexion contracture formation at the right elbow and generalized muscle wasting of the right upper extremity. Erythema and warmth was not observed overlying the right chest wall tunneled central venous access device. No skin eruptions, nodules, rash, or nailbed abnormalities were found. Bedside ophthalmologic fundus examination was unremarkable. The pulmonary and abdominal findings were normal.

Laboratory examinations showed that the peripheral white blood cell count was 10,580 cells/µL (normal range 3950-11,350 cells/µL) with neutrophils 62%, lymphocytes 28%, monocytes 6%, and eosinophils 3%. His red blood cell evaluation showed hemoglobin and hematocrit values at 8.0 g/dL and 23.4%, respectively, and evidence of hemolysis with lactate dehydrogenase at 332 U/L (normal range, 81-234 U/L). Elevated serum levels of C-reactive
protein (7.9 mg/dL, normal range 0.3-0.9 m/dL) and erythrocyte sedimentation rate (32 mm/hr, normal range 0-15 mm/hr) were observed. The serum creatinine was 0.7 mg/dL (normal range 0.8-1.3 mg/dL) with an estimated glomerular filtration ratio of 150 mL/min. No other abnormalities were detected on laboratory testing including negative blood and urine toxicology screening. Two view plain-film imaging of the chest revealed no abnormalities. In addition, two sets of blood culture specimens (2 aerobic bottles and 2 anaerobic bottles) from the central venous access device and peripheral veins were inoculated into BACTEC standard culture bottles in a BACTEC 9000 system (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). *Bacillus cereus*, identified eventually upon gram-stain, gross colony morphology, endospore stains, and matrix-assisted laser desorption ionization-time of flight mass spectroscopy (MALDI-TOF MS) protocol, grew in all admission blood cultures. Blood cultures through the central venous access port grew within 6-hours while peripheral blood grew within 10-hours of obtaining samples. Vancomycin 1.25 grams intravenous every 8 hours (15mg/kg dosing protocol) in combination with piperacillin-tazobactam 3.375 grams intravenous every 8 hours treatment was initiated empirically prior to blood culture identification.

Antimicrobial susceptibility was determined with the MicroScan WalkAway system (Dade Behring, Deerfield, IL) and the standard criteria of the Clinical and Laboratory Standards Institute (CLSI) (4). Breakpoint susceptibility testing was performed using the broth microdilution method with eight antimicrobial agents based upon the recommendations of the CLSI document M24-A2E (4) for the following agents: ciprofloxacin, clindamycin, erythromycin, gentamicin, rifampin, and vancomycin (TABLE 1). For other antimicrobials (penicillin and tetracycline), the breakpoints for *Staphylococcus* spp. in the CLSI guideline M 100-S22 (5) and...
S24 (6) were used. Based upon culture reporting, the antimicrobial treatment was switched to vancomycin monotherapy with subsequent blood cultures becoming negative 1-week later.

The patient’s clinical scenario supported the diagnosis of a long-term catheter-related bloodstream infection (CRBSI) according to the published criterion from the Infectious Diseases Society of America (IDSA) for both quantitative blood cultures and differential time to positivity (DTP) (7). Therefore the patient underwent further examination by both transthoracic and transesophageal echocardiography (7). Two-dimensional, M-mode transthoracic echocardiography (TTE) noted only an ill-defined echogenic density involving the right atrium and indwelling central venous catheter (FIGURE 1). Transesophageal echocardiography (TEE; FIGURE 2) demonstrated multiple mobile echogenic densities involving the right atrium and tricuspid valve. Tricuspid valvular regurgitation was noted as a new change in comparison to older studies performed at the time of central venous catheter placement and prior stroke. Additionally, contrast enhanced computed tomography (CT) imaging of the chest demonstrated multiple small pulmonary parenchymal defects consistent with septic emboli. Based upon these findings the patient was classified as definite infective endocarditis with two major criterion (e.g. oscillating intracardiac and valvular masses as well as new valvular regurgitation) by modifications to the Duke’s criteria for the diagnosis of infective endocarditis (8). The patient also met defined criteria for “possible infective endocarditis” with at least one major and one minor manifestation (8).

Surgical extraction of the tunneled central venous access site was performed followed 72-hours later by placement of a peripherally inserted central venous catheter (PICC) in the left basilic vein for long-term intravenous antimicrobial therapy. Vancomycin monotherapy was

*Bacillus cereus* endocarditis
continued for 6-weeks after the first negative set of blood cultures following extraction of the device. Clinically, the patient had cessation of his sickle crisis, resolution of symptoms, normalization of laboratory parameters, and unremarkable end-of-therapy echocardiography examination.

Discussion

Endocarditis attributed to *Bacillus cereus* and other related species are considered uncommon with few large epidemiological or clinical studies of these types of infections (1, 2, 3). Therefore a review of the published literature was performed by conducting a PubMed search of past case reports and case series from 1963 to 2015 (9) with search terms “*Bacillus cereus* and endocarditis”, “*Bacillus* species and endocarditis”, “*Bacillus cereus* and catheter related bloodstream infection”, *Bacillus* species and catheter related bloodstream infection”, “*Bacillus cereus* and antimicrobial susceptibility”, and “*Bacillus* species and antimicrobial susceptibility”; however, this discussion will mainly focus on *Bacillus cereus* related endocarditis.

Members of the *Bacillus cereus* group consist of genotypically and phenotypically closely related species to include: *B. anthracis*, *B. cereus*, *B. mycoides*, *B. pseudomycoide*, *B. thuringiensis*, and *B. weihenstephanensis* (1). The most common pathogen implicated in non-anthrax related infections is *Bacillus cereus* (1-3). The combination of motility and production of exotoxins, particularly hemolysins (four), phospholipases (three), emetic-toxin (one), and enterotoxins (three), are responsible for the bacteria’s ability to cause devastating tissue necrosis in the absence of trauma (1, 2). Laboratory examination of the bacteria typically
reveals a slender, relatively straight or slightly curved, square end gram-positive rod with an oval centralized endospore (1). *Bacillus* species usually produce good growth on aerobic 5% sheep blood agar following 24-48h of incubation with satisfactory identification using commercial systems such as API Enterobacteriaceae (API 20) and API 50 Carbohydrate (50 CH) kits (bioMerieux, France) (1). *B. cereus* is aerotolerant and grows readily as swarming, flat and dull gray or opaque colonies with a narrow zone of beta-hemolysis on aerobic blood agar (1, 2).

Recognition of systemic infection caused by non-anthrax *Bacillus* spp. began in 1963 with Farrar’s review of 12 cases reported in the world literature (9). Finland and Barnes (10) in their review first reported three cases (two cases in 1933 and one case in 1951) with gram-positive bacillus (not specifically reported as organisms of the genus *Bacillus*) endocarditis at Boston City Hospital. Endocarditis caused by nonpathogenic organisms of the genus *Bacillus* (*B. subtilis*) was first reported in 1973 with an intravenous drug-abusing (IVDA) patient (11). Subsequently, *Bacillus cereus* endocarditis with first reported in 1974 with a young female heroin addict (12). Since then, twenty-six additional cases of *Bacillus* spp. related endocarditis have been reported in the literature (TABLE 2) (13-35). While *Bacillus cereus* is the most commonly reported pathogen (78.5%; n = 22), other associated species include: *B. circulans* (2 cases), *B. licheniformis* (1 case), *B. popilliae* (1 case), *B. pumilus*, and *B. subtilis* (1 case). Males are reported more common than females (42.8% vs 25.0%) with an age distribution as: 10-21 years (3.6%; n = 1), 21-40 (14.2%; n = 4), 41-60 (35.7%; n = 10), and age greater than 60 years (14.2%; n = 4). Disease most commonly involved the aortic valve (15, 17, 19, 20, 22, 25, 26, 31, 34) followed by the mitral (13, 21, 23, 24, 28, 54) and tricuspid valve (12, 35), respectively.

When *Bacillus* spp. are found to be the causative pathogen of endocarditis they are typically...
associated with intravenous drug-abuse (IVDA) history (11, 12, 14, 16, 34, 35), leukemia (28), preexisting cardiac or valvular heart disease (Atrial septal defect; Bicuspid aortic valve; Patent foramen ovale; Rheumatic heart disease) (12, 18, 19, 22, 25-27, 32), prosthetic heart valve (13, 17, 20-25, 27), pacemaker/implantable cardioverter defibrillator (ICD) (18, 29, 30, 33), and pregnancy (35). This report describes the twenty-ninth overall case of Bacillus spp. related endocarditis, twenty-second involving Bacillus cereus, third tricuspid valve disease, and first involving SCD with a tunneled medical port central venous catheter in a patient without IVDA.

Previous reports suggest IVDA (11, 12, 14, 16, 34-36) and indwelling central venous catheters (37-40) as risk factors most commonly associated with Bacillus spp. related bacteremia. Bacteremia most likely originates from cutaneous colonization and/or contamination of drug agents and injection equipment (31, 35-40). Tuazon et al (36), when comparing bacterial cultures among 100 samples each of heroin and injection paraphernalia, found Bacillus spp. could be cultured from 32 and 47%, respectively. In a retrospective evaluation by Kassar et al (40) of 94 adult patients with Bacillus bloodstream infection (2054 positive blood cultures) at a tertiary medical center between 1990 and 2008, more than half (71%) of the cases were defined as probable CRBSI followed by definite CRBSI in 28% of cases. The association between Bacillus spp. and intravascular devices results mainly from high exopolymer production (biofilm formation) (40). Other studies have demonstrated the presence of Bacillus cereus within ethanol containing preparations as well as hospital linens and towels in association with nosocomial related bacteremia (41-43).

Most of the patients listed in Table 2, including this case, did not have IVDA history related Bacillus bloodstream infection. While IVDA-associated prosthetic valve infection
responded to valve replacement and systemic antimicrobial therapy, native valve IVDA-associated infections typically responded to antimicrobial therapy alone. In this case the presence of a long-term central venous catheter provides the most probable explanation of how the organism gained access to cause infection; however, it cannot be ruled out the role of many previous hospitalizations for sickle cell crisis may have played in this case. Previous studies have reported resolution of *Bacillus* spp. related CRBSI with central venous catheter removal (38-40) and, therefore, this patient was treated with both catheter removal and systemic antimicrobial therapy.

The patient under discussion was eventually diagnosed with *Bacillus cereus* related endocarditis based upon admission blood cultures, evidence supporting long-term CRBSI, and echocardiographic findings. This case was classified as both “possible infective endocarditis” with at least one major and one minor manifestation and “definite infective endocarditis” with two major criterion (e.g. oscillating intracardiac and valvular masses as well as new valvular regurgitation) by modifications to the Duke’s criteria for the diagnosis of infective endocarditis (8). New tricuspid valvular regurgitation was based upon prior normal transthoracic echocardiogram reports at the time of central venous catheter placement and stroke. While the majority of patients listed in **TABLE 2** fulfilled the criterion of possible infective endocarditis with one major manifestation (positive echocardiogram) and minor manifestation (predisposing heart condition or injection drug use), it is unclear from the available data if cases met the strict criterion of definite infective endocarditis (e.g. two major criteria; one major criterion and three minor criteria; or five minor criteria) (8).
Regarding treatment, patients listed in TABLE 2 exhibit varying antimicrobial regimens for most commonly a duration of 6-weeks. According to antimicrobial susceptibility studies, *Bacillus cereus* appears to be uniformly sensitive to gentamicin, imipenem, and vancomycin (44-48). In general, three separate trials by Weber et al (44), Luna et al (46), and Veysseyre et al (48) report all tested strains (100%; n = 240) susceptible to gentamicin, imipenem, and vancomycin. Most strains were variably resistant to amoxicillin (40%), cefazolin (55%), ceftriaxone (40%), ciprofloxacin (41%), clindamycin (20%), and penicillin (100%) (44, 46, 48). Luna et al (46) reported all forty-two *Bacillus cereus* isolates susceptible to daptomycin, linezolid, and tigecycline. Ikeda et al (47) reported a retrospective single-center trial involving 29 evaluable patient to document the clinical and antimicrobial susceptibility characteristics of *Bacillus cereus* nosocomial bloodstream infections as well as whether appropriate empirical treatment (n=9) or inappropriate empirical treatment (n=20) had been initiated at admission (defined as susceptible antimicrobial agents). No significant difference existed in the clinical responses of the two groups with all-cause mortality but early defervescence occurred more often with appropriate empirical therapy rather than inappropriate empirical antimicrobial therapy. Authors reported 65.5% of isolates resistant to clindamycin and 10.3% resistant to levofloxacin. Empirical antimicrobial is often initiated prior to culture at the time of evaluation with emergency medicine providers followed by modification with susceptibility date; therefore, the most appropriate empirical choices include daptomycin, imipenem, linezolid, tigecycline, or vancomycin. Although the patient reported in this current case was empirically treated with vancomycin 1.25 grams intravenous every 8 hours (15mg/kg dosing protocol) in combination with piperacillin-tazobactam 3.375 grams intravenous every 8 hours, his strain
demonstrated resistance only to ampicillin and intermediate susceptibility to clindamycin (TABLE 1). Based upon susceptibility testing vancomycin monotherapy was continued for 6-weeks after the first negative set of blood cultures following extraction of the device. Clinically, the patient had cessation of his sickle crisis, resolution of crisis related symptoms, normalization of laboratory parameters, and unremarkable end-of-therapy transthoracic echocardiography examination with mild residual tricuspid regurgitation but complete resolution of valvular vegetations.

Although this patient was reported as afebrile with a normal peripheral leukocyte count, it is not clear whether this represents a typical or atypical clinical presentation because of the lack of data and varying reports with previous cases. In contrast, Kassar et al (40) reported 88% of patients (83/93) had a fever (defined as greater than 38.0 C) among 94 episodes of Bacillus spp. related bloodstream infections. Additionally, Ikeda et al (47) reported an average white blood cell count of 7497 cells/µL (reported range of 100-22,200 cells/µL) among 29 patients with Bacillus cereus related bloodstream infections. Therefore, further evaluations are needed to elucidate clinical characteristics for patients with Bacillus spp. related endocarditis.
Conclusion

This report describes a case of the first patient with Bacillus cereus related endocarditis in association with SCD and a medical port central venous catheter as well as a literature review. Given that Bacillus spp. related endocarditis is uncommon this case highlights an aggressive need to further investigate and interpret unexpected blood culture findings in clinical practice. Another important lesson from this case report and literature review would suggest early adequate antimicrobial therapy, prompt diagnosis, and consideration to urgent surgical interventions with either valve replacement or device extraction. Finally, recognition of infections due to unusual pathogens warrants further evaluation and appropriate management in association with infectious diseases consultation.
References


45. Turnbull PCB, Sirianni NM, LeBron CI, et al. MICs of selected antibiotics for _Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis_, and _Bacillus mycoides_ from a range of

46. Luna VA, King DS, Gulledge J, Cannons AC, Amuso PT, Cattani J. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoideae and Bacillus thuringiensis to 24 antimicrobials using Sensititre(R) automated microbroth dilution and Etest(R) agar gradient diffusion methods. J Antimicrob Chemother. 2007;60(3):555-567. doi:10.1093/jac/dkm213. Medline


Author Affiliation
William F. Wright, DO, MPH, FCAP; Division of Infectious Diseases, Department of Medicine, Memorial Medical Center, 1600 Sixth Avenue, Suite 114, York, Pennsylvania 17403-2643
**TABLE 1. Minimal Inhibitory Concentrations for *Bacillus cereus* isolates**

<table>
<thead>
<tr>
<th>Antimicrobial agent</th>
<th>* MIC, µg/mL</th>
<th>‡ Susceptibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin</td>
<td>&gt;8</td>
<td>R</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>≤ 1</td>
<td>S</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>1</td>
<td>I</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>≤ 0.2</td>
<td>S</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>≤ 1</td>
<td>S</td>
</tr>
<tr>
<td>Rifampin</td>
<td>≤ 1</td>
<td>S</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>≤ 1</td>
<td>S</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>1</td>
<td>S</td>
</tr>
</tbody>
</table>

*MIC = minimum inhibitory concentration

‡ R = resistance; S = susceptible; I = intermediate
**TABLE 2. Summary for cases of Bacillus spp. endocarditis.**

<table>
<thead>
<tr>
<th>Year [ref]</th>
<th>Bacillus species</th>
<th>Age [sex]</th>
<th>a Risk factor(s)</th>
<th>Valve</th>
<th>b Antimicrobial therapy [duration]</th>
<th>Clinical Outcome [surgical repair]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year</td>
<td>Organism</td>
<td>Sex</td>
<td>Age</td>
<td>Diagnosis</td>
<td>Device Site</td>
<td>Treatment</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>-----</td>
<td>-----</td>
<td>--------------------</td>
<td>-------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>2008</td>
<td><em>B. cereus</em></td>
<td>F</td>
<td>69</td>
<td>PM</td>
<td>Wire</td>
<td>Cfx [6 weeks]</td>
</tr>
<tr>
<td>2011</td>
<td><em>B. cereus</em></td>
<td>M</td>
<td>42</td>
<td>None</td>
<td>Aortic</td>
<td>Cro [6 weeks]</td>
</tr>
<tr>
<td>2012</td>
<td><em>B. cereus</em></td>
<td>M</td>
<td>54</td>
<td>VHD</td>
<td>Mitral</td>
<td>NR [6 weeks]</td>
</tr>
<tr>
<td>2012</td>
<td><em>B. cereus</em></td>
<td>M</td>
<td>65</td>
<td>PM</td>
<td>Wire</td>
<td>Ofx, Pip [4 weeks]</td>
</tr>
<tr>
<td>2013</td>
<td><em>B. cereus</em></td>
<td>M</td>
<td>31</td>
<td>IVDA</td>
<td>Aortic</td>
<td>Cxm [6 weeks]</td>
</tr>
<tr>
<td>2015</td>
<td><em>B. cereus</em></td>
<td>F</td>
<td>30</td>
<td>IVDA,*Prg</td>
<td>Tricuspid</td>
<td>Van [6 weeks]</td>
</tr>
<tr>
<td>Current case</td>
<td><em>B. cereus</em></td>
<td>M</td>
<td>27</td>
<td>MP-CVC</td>
<td>Tricuspid</td>
<td>Van [6 weeks]</td>
</tr>
</tbody>
</table>

**NR**, not reported

* ALL, acute lymphoblastic leukemia; ASD, atrial septal defect; AA, alcoholic abuse; BAV, bicuspid aortic valve; ICD, implantable cardioverter defibrillator; IVDA, intravenous drug abuse; MP-CVC, medical port central venous catheter; PFO, patent foramen ovale; PM, pacemaker; PV, prosthetic valve; RHD, rheumatic heart disease; VHD, valvular heart disease

* Amk, amikacin; Cfx, cefazolin; Chl, chloramphenicol; Cip, ciprofloxacin; Cli, clindamycin; Cro, ceftriaxone; Cxm, cefuroxime; Ery, erythromycin; Gen, gentamicin; Kan, kanamycin; Lm, lincomycin; Min, minocycline; Naf, nafcillin; Pen, penicillin; Rif, rifampin; Str, streptomycin; Sxt, trimethoprim-sulfamethoxazole; Tob, tobramycin; Van, vancomycin

* *Prg*, the patient was 25-weeks pregnant at the time of presentation with normal delivery at 37-weeks.
FIGURE 1. Standard 2-D transthoracic echocardiogram (TTE) apical four chamber view with focus to the right atrium (RA) and ventricle (RV) demonstrating an ill-defined echogenic dense lesion (V) within the right atrium attached to the Medical Port central venous catheter.
FIGURE 2. Mid-esophageal transesophageal echocardiogram (TEE) window (typically at 30-40 cm with an angle range of 0-20 degrees) demonstrating an echogenic dense lesion (V) within the right atrium (RA) attached to the atrial surface of the tricuspid valve (TV). The left atrium (LA) and right ventricle (RV) are also pictured in this view.